Miguel Teodoro
Hernández García
Profesor Asociado Asistencial
Hospital Clinico Universitario de Valencia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (20)
2022
-
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100
-
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)
Leukemia and Lymphoma, Vol. 63, Núm. 14, pp. 3438-3447
-
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group
Blood cancer journal, Vol. 12, Núm. 4, pp. 76
2021
-
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
Blood Cancer Journal, Vol. 11, Núm. 5
2020
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
2019
-
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)
Leukemia
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal, Vol. 9, Núm. 4
2018
-
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Leukemia, Vol. 32, Núm. 11, pp. 2427-2434
-
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
PLoS ONE, Vol. 13, Núm. 9
-
Prognostic value of antigen expression in multiple myeloma: A PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
Leukemia, Vol. 32, Núm. 4, pp. 971-978
2017
-
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
Leukemia
-
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA/GEM trial
Leukemia, Vol. 31, Núm. 9, pp. 1922-1927
-
Depth of response in multiple myeloma: A pooled analysis of three PETHEMA/GEM clinical trials
Journal of Clinical Oncology, Vol. 35, Núm. 25, pp. 2900-2910
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
-
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Blood, Vol. 127, Núm. 25, pp. 3165-3174
-
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM
Blood, Vol. 127, Núm. 4, pp. 420-425
2012
-
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
Blood, Vol. 119, Núm. 3, pp. 687-691
-
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: A randomized phase 3 PETHEMA/GEM study
Blood, Vol. 120, Núm. 8, pp. 1589-1596
2011
2008
-
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression
Haematologica, Vol. 93, Núm. 4, pp. 560-565